clinical study

Vivus Adds 12% in Early Trading on Qnexa Study Results

blood pressure, clinical study, diet, drug, fat, health, lipid, medical, medication, obesity, pharma, pill, placebo, qnexa, trade, vivus, vvus, weight loss

Vivus (VVUS) is up by double digits in early trading, after it says long-term data demonstrated patients treated with the investigational drug QNEXA for two years showed reductions in blood pressure and the use of antihypertensive

By FNNO Staff
fnnonline@gmail.com

Latest News from FNNO

Shares of YRC Worldwide Have Risen Above...

Shares of YRC Worldwide (NASDAQ:YRCW) traded at a new 52-week high today of $30.49. Th ...

Watch for Continued Gains in Shares of T...

Shares of TRW Automotive (NYSE:TRW) traded at a new 52-week high today of $66.79. Appr ...

Shares of Sierra Wireless Rise Above Pre...

Sierra Wireless (NASDAQ:SWIR) traded at a new 52-week high today of $13.03. This new h ...

Seagate Technology: 52-Week High Recentl...

Shares of Seagate Technology (NASDAQ:STX) traded at a new 52-week high today of $45.50. ...

Reinsurance Group of America: The Winnin...

Reinsurance Group of America (NYSE:RGA) traded today at a new 52-week high of $69.15. ...

Targa Resources Partners: 52-Week High R...

Shares of Targa Resources Partners (NASDAQ:NGLS) traded at a new 52-week high today of ...

Recent 52-Week High Exceeded in Shares o...

Shares of Hospira (NYSE:HSP) traded today at $38.50, breaking its 52-week high. Approx ...

Shares of Heartland Payment Systems Rise...

Heartland Payment Systems (NYSE:HPY) traded today at a new 52-week high of $37.17. So ...

Most Popular Video News